Tag Archives: biosimilars
Innovators: Take a Leaf from the Generic Industry Book
No-one can accuse the European generic industry of indolence. It supplies huge quantities of medicines to European healthcare suppliers — its volume is estimated at around a half of the market. It is accounting for a growing share of marketing authorization applications in Europe. And its industry association, the EGA, has turned it from being [...]
Posted in Europe, Regulatory, healthcare Also tagged anti-competitive strategies, antitrust, EC, EGA, EU, European Generics, generics, healthcare Leave a comment
MedImmune Bets Its Fate on “Biobetters”
AstraZeneca’s biologics shop makes a decisive move in the biosimilars market.
MedImmune, the biologics shop bought by AstraZeneca (AZ) for a staggering $15 billion in 2007 promising one new drug a year for the foundering British firm, has made precious little news since the deal. But all of a sudden the post-Labor Day wires were crackling [...]
US and Europe At Risk from Substandard Medicines
Guest blog by Helen Disney, Chief Executive and Founder of the Stockholm Network, a pan-European think tank.
When most of us look at taking a new medicine we tend to think it will make us better. Some of us may think about possible side effects but few of us expect the medicines we take to actually [...]
Posted in Biotech, Emerging Markets, Europe, Global, Guest Blog, Regulatory, Safety Also tagged Brazil, China, counterfeit medicines, developing nations, Emerging Markets, Europe, Indian, Regulatory, substandard medicines, Turkey, US Leave a comment

Biosimilars Spend to Reach $2.5 Bln by 2015: IMS